Intraoperative radiotherapy for breast cancer
- PMID: 25083504
- PMCID: PMC4115764
- DOI: 10.3978/j.issn.2227-684X.2014.03.03
Intraoperative radiotherapy for breast cancer
Abstract
Intra-operative radiotherapy (IORT) as a treatment for breast cancer is a relatively new technique that is designed to be a replacement for whole breast external beam radiotherapy (EBRT) in selected women suitable for breast-conserving therapy. This article reviews twelve reasons for the use of the technique, with a particular emphasis on targeted intra-operative radiotherapy (TARGIT) which uses X-rays generated from a portable device within the operating theatre immediately after the breast tumour (and surrounding margin of healthy tissue) has been removed. The delivery of a single fraction of radiotherapy directly to the tumour bed at the time of surgery, with the capability of adding EBRT at a later date if required (risk-adaptive technique) is discussed in light of recent results from a large multinational randomised controlled trial comparing TARGIT with EBRT. The technique avoids irradiation of normal tissues such as skin, heart, lungs, ribs and spine, and has been shown to improve cosmetic outcome when compared with EBRT. Beneficial aspects to both institutional and societal economics are discussed, together with evidence demonstrating excellent patient satisfaction and quality of life. There is a discussion of the published evidence regarding the use of IORT twice in the same breast (for new primary cancers) and in patients who would never be considered for EBRT because of their special circumstances (such as the frail, the elderly, or those with collagen vascular disease). Finally, there is a discussion of the role of the TARGIT Academy in developing and sustaining high standards in the use of the technique.
Keywords: Early breast cancer; Intrabeam; intra-operative radiotherapy (IORT); radiotherapy; targeted intra-operative radiotherapy (TARGIT).
Figures


Similar articles
-
An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).Health Technol Assess. 2016 Sep;20(73):1-188. doi: 10.3310/hta20730. Health Technol Assess. 2016. PMID: 27689969 Free PMC article.
-
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.BMJ. 2020 Aug 19;370:m2836. doi: 10.1136/bmj.m2836. BMJ. 2020. PMID: 32816842 Free PMC article. Clinical Trial.
-
Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A.Radiat Oncol. 2013 Jan 7;8:9. doi: 10.1186/1748-717X-8-9. Radiat Oncol. 2013. PMID: 23294485 Free PMC article. Clinical Trial.
-
Breast-conserving surgery with intra-operative radiotherapy: the right approach for the 21st century?Clin Oncol (R Coll Radiol). 2006 Apr;18(3):220-8. doi: 10.1016/j.clon.2005.11.017. Clin Oncol (R Coll Radiol). 2006. PMID: 16605053 Review.
-
Is IORT ready for roll-out?Ecancermedicalscience. 2015 Mar 12;9:516. doi: 10.3332/ecancer.2015.516. eCollection 2015. Ecancermedicalscience. 2015. PMID: 25793013 Free PMC article. Review.
Cited by
-
Rhopalurus junceus scorpion venom induces apoptosis in the triple negative human breast cancer cell line MDA-MB-231.J Venom Res. 2017 Apr 16;8:9-13. eCollection 2017. J Venom Res. 2017. PMID: 29285349 Free PMC article.
-
Cardiac serum marker alterations after intraoperative radiotherapy with low-energy x-rays in early breast cancer as an indicator of possible cardiac toxicity.Strahlenther Onkol. 2021 Jan;197(1):39-47. doi: 10.1007/s00066-020-01671-3. Epub 2020 Aug 19. Strahlenther Onkol. 2021. PMID: 32813034 Free PMC article.
-
Intraoperative radiation therapy deserves to be made more readily available to patients.Chin J Cancer Res. 2016 Aug;28(4):461-2. doi: 10.21147/j.issn.1000-9604.2016.04.10. Chin J Cancer Res. 2016. PMID: 27647975 Free PMC article. No abstract available.
-
Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer.Cancer Cell Int. 2020 Sep 11;20:446. doi: 10.1186/s12935-020-01533-z. eCollection 2020. Cancer Cell Int. 2020. PMID: 32943994 Free PMC article.
-
Advantages of intraoperative implant for interstitial brachytherapy for accelerated partial breast irradiation either frail patients with early-stage disease or in locally recurrent breast cancer.J Contemp Brachytherapy. 2018 Apr;10(2):97-104. doi: 10.5114/jcb.2018.75594. Epub 2018 Apr 30. J Contemp Brachytherapy. 2018. PMID: 29789758 Free PMC article.
References
-
- Vinh-Hung V, Verschraegen C.Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004;96:115-21 - PubMed
-
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) , Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-16 - PMC - PubMed
-
- Keshtgar M, Davidson T, Pigott K, et al. Current status and advances in management of early breast cancer. Int J Surg 2010;8:199-202 - PubMed
-
- Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46 - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases